close read more

Corporate Social Responsibility

Publication of the 2019 CSR report

Read more

Home - Servier

logo twitter

Employees in  66 countries,
including  5,000 in France.

100 million

patients treated each day worldwide with Servier medicines.

25 %

of revenue from brand-name medicines invested in R&D each year on average.

4.6 billion

euros in revenue in 2018/2019 comprising €3.2 billion for brand-name medicines and €1.4 billion for generic medicines.

5 therapeutic areas

cardiovascular, cancer, diabetes immune-inflammatory and neuropsychiatric diseases.

icon play
icon play

Join our teams!

We do everything possible for all Group employees to have the means to succeed, to adapt, to take on responsibilities and to grow. At Servier, you will be offered a unique and meaningful professional experience.

R&D: To accelerate therapeutic innovation

To discover new treatments that improve patients’ lives, the Group focuses its research and development efforts in therapeutic areas where needs are substantial.

Our Group’s corporate social responsibility

The Mécénat Servier Charity Fund is one of the main aims of our CSR strategy, and a natural extension of our commitment to therapeutic progress to serve patient needs.

The basis for our actions

Because passing on to future generations a world that can ensure access to quality health care for all is our vision for the future, at Servier, all over the world, we are ready to meet the health care challenges of tomorrow, for and with patients. Discover our corporate video.

icon play